英国扩大RSV防线!辉瑞(PFE.US)RSV疫苗覆盖范围从75岁扩至80岁以上

智通财经04-02

智通财经APP获悉，美国医药巨头辉瑞公司(PFE.US)所推出的用于预防一种可能具有极度危险性的呼吸道感染疾病的疫苗产品，将通过英国国有的国民保健服务体系(NHS)向英格兰另外约300万人提供。据了解，英格兰地区所有80岁及以上的成年人都将有资格接种这款名为Abrysvo的疫苗，以预防呼吸道合胞病毒(RSV)。这种病毒可引发严重支气管炎和肺炎。周四公布的这一决定是在现有项目基础上的全面扩展，此前该...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2624526907?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-02 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624526907","market":"us","top_or_hot":-1,"title":"英国扩大RSV防线!辉瑞(PFE.US)RSV疫苗覆盖范围从75岁扩至80岁以上","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，美国医药巨头辉瑞公司(PFE.US)所推出的用于预防一种可能具有极度危险性的呼吸道感染疾病的疫苗产品，将通过英国国有的国民保健服务体系(NHS)向英格兰另外约300万人提供。据了解，英格兰地区所有80岁及以上的成年人都将有资格接种这款名为Abrysvo的疫苗，以预防呼吸道合胞病毒(RSV)。这种病毒可引发严重支气管炎和肺炎。周四公布的这一决定是在现有项目基础上的全面扩展，此前该...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1424371.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>英国扩大RSV防线!辉瑞(PFE.US)RSV疫苗覆盖范围从75岁扩至80岁以上</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n英国扩大RSV防线!辉瑞(PFE.US)RSV疫苗覆盖范围从75岁扩至80岁以上\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-02 09:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1424371.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，美国医药巨头辉瑞公司(PFE.US)所推出的用于预防一种可能具有极度危险性的呼吸道感染疾病的疫苗产品，将通过英国国有的国民保健服务体系(NHS)向英格兰另外约300万人提供。据了解，英格兰地区所有80岁及以上的成年人都将有资格接种这款名为Abrysvo的疫苗，以预防呼吸道合胞病毒(RSV)。这种病毒可引发严重支气管炎和肺炎。周四公布的这一决定是在现有项目基础上的全面扩展，此前该...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1424371.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999002232.USD","symbol_name":"Allianz Global High Payout USD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1424371.html","article_id":"2624526907","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624526907","pubTimestamp":1775093611,"columns":[{"name":"产品发布","id":31,"label_key":"productRelease"}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"周四公布的这一决定是在现有项目基础上的全面扩展，此前该项目覆盖的是75岁至79岁人群。葛兰素史克在英国推出的是一款面向老年人的竞争性疫苗，而阿斯利康则在英国推出的是一款用于保护婴儿免受RSV侵害的药物。RSV疫苗对老年群体可谓非常重要，可以说是高龄呼吸道预防体系中的关键一环。英国方面之所以把辉瑞Abrysvo的接种范围从75至79岁扩大到80岁及以上，重要依据之一则是上述的新证据显示，接种后因RSV住院的风险可下降约75%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","BK4592":"伊斯兰概念","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4550":"红杉资本持仓","BK4588":"碎股","BK4568":"美国抗疫概念","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","PFE":"辉瑞","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4007":"制药","SG9999001176.USD":"United Global Healthcare Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4581":"高盛持仓","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4599":"减肥药"},"translate_title":"UK Expands RSV Line! Pfizer (PFE.US) Expands RSV Vaccine Coverage from 75 to Over 80","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1.97},"content_text":"智通财经APP获悉，美国医药巨头辉瑞公司(PFE.US)所推出的用于预防一种可能具有极度危险性的呼吸道感染疾病的疫苗产品，将通过英国国有的国民保健服务体系(NHS)向英格兰另外约300万人提供。据了解，英格兰地区所有80岁及以上的成年人都将有资格接种这款名为Abrysvo的疫苗，以预防呼吸道合胞病毒(RSV)。这种病毒可引发严重支气管炎和肺炎。周四公布的这一决定是在现有项目基础上的全面扩展，此前该项目覆盖的是75岁至79岁人群。英国国家卫生安全局表示，新的临床研究证据显示，接种该项疫苗可将因该感染而住院的风险降低约75%。英国当局最初选择的是辉瑞这款疫苗来同时保护本国老年人和婴儿群体，此举被视为对本土制药巨头葛兰素史克公司和阿斯利康公司的冷落。葛兰素史克在英国推出的是一款面向老年人的竞争性疫苗，而阿斯利康则在英国推出的是一款用于保护婴儿免受RSV侵害的药物。在英国NHS体系里，辉瑞Abrysvo目前是获批的唯一一款同时用于“老年人项目”和“婴儿保护项目”的RSV疫苗产品;不过婴儿这条线不是直接给婴儿打，而是给孕妇接种，通过母体抗体来保护新生儿，即给孕28周起的孕妇接种，通过母体抗体保护新生儿。其他相关产品并没有在NHS里以同样方式同时承担这两类项目，阿斯利康在英国对应的是婴儿保护药物，葛兰素史克的Arexvy则是老年人竞品。RSV疫苗对老年群体可谓非常重要，可以说是高龄呼吸道预防体系中的关键一环。美国CDC指出，每年美国50岁及以上成人因RSV住院的人数约为11万至18万，而重症风险会随年龄上升而明显增加;CDC当前也因此建议75岁及以上所有成年人，以及50至74岁高风险人群接种RSV疫苗。英国方面之所以把辉瑞Abrysvo的接种范围从75至79岁扩大到80岁及以上，重要依据之一则是上述的新证据显示，接种后因RSV住院的风险可下降约75%。目前美国市场获批的用于预防老年成人RSV下呼吸道疾病的成人疫苗共有三款：辉瑞Abrysvo、葛兰素史克Arexvy以及Moderna mRESVIA;Abrysvo无疑属于第一梯队，FDA披露的临床数据显示，Abrysvo在老年人中将RSV相关下呼吸道疾病风险降低了66.7%(按≥2个症状定义)和85.7%(按≥3个症状定义);辉瑞后续又公布，两季后对“≥3个症状的RSV下呼吸道疾病”保护效力仍高达77.8%。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624526907","isCrawlerRequest":true}